Skip to main content
All Posts By

laurabbook@gmail.com

journal of thoracic oncology
Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation ResearchTreatments

Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation

*August 2021* Introduction Management of central nervous system (CNS) metastases in patients with driver-mutated NSCLC has traditionally incorporated both tyrosine kinase inhibitors (TKIs) and intracranial radiation. Whether next generation, CNS-penetrant TKIs can be used alone without upfront radiation, however, remains unknown. This multi-institutional retrospective analysis aimed to compare outcomes in…
laurabbook@gmail.com
November 10, 2021
Multicenter Analysis of Mechanisms of Resistance to Osimertinib in EGFR Mutated NSCLC: An ATOMIC Registry Study ResearchTreatments

Multicenter Analysis of Mechanisms of Resistance to Osimertinib in EGFR Mutated NSCLC: An ATOMIC Registry Study

*January 2021* The ATOMIC consortium is a group of thoracic oncologists from North America. They received funding from AstraZeneca to build a registry of patients with EGFR+ NSCLC. The registry contains all treatments given, molecular tests performed, and radiologic results.The registry contains data on 1187 patients with EGFR+ NSCLC. This…
laurabbook@gmail.com
March 7, 2021
targeted oncology
Patritumab Deruxtecan Shows Early Activity in Metastatic EGFR-Mutant NSCLC ResearchTreatments

Patritumab Deruxtecan Shows Early Activity in Metastatic EGFR-Mutant NSCLC

*January 2021* Patritumab deruxtecan demonstrated early and clinically meaningful activity in pretreated patients with metastatic or unresectable EGFR-mutant non–small cell lung cancer in the results of a phase 1 trial that were presented during the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore.…
laurabbook@gmail.com
March 6, 2021
Diversifying Clinical Trial Inclusion Criteria: Currrent Challenges and Potential Solutions Advocacy

Diversifying Clinical Trial Inclusion Criteria: Currrent Challenges and Potential Solutions

*January 2021* Jill Feldman, co-founder of the EGFR Resisters, presented on Diversifying Clinical Trial Inclusion Criteria: Currrent Challenges and Potential Solutions to help ensure every decision, starting at concept is looked at through a health equity lens. Creating clinical trials WITH us not just FOR us! It is a moral imperative…
laurabbook@gmail.com
March 6, 2021
ResearchTreatments

Ask the Experts: Progression and Resistance

*January 2021* The first of three webinars on Progression and Resistance in EGFR+ lung cancer. This first webinar is on Histological Transformation, featuring small cell transformation. Dr Helena Yu and Dr Joseph Chan, both from Memorial Sloan Kettering in New York, provide their expertise. There is a control bar at the…
laurabbook@gmail.com
January 21, 2021
Enriching Responses With Targeted Therapy in NSCLC ResearchTreatments

Enriching Responses With Targeted Therapy in NSCLC

*December 2020* EGFR, ALK, and ROS1 abnormalities are no longer the only oncogenic drivers worthy of discussion in non–small cell lung cancer (NSCLC), explained Stephen Liu, MD, who added that the field has seen an abundance of highly selective RET, MET, HER2, and KRAS inhibitors that have the potential to deliver durable responses.…
laurabbook@gmail.com
January 21, 2021
Genetic Heterogeneity of MET-aberrant Non-Small Cell Lung Cancer and its Impact on the Outcome of Immunotherapy ResearchTreatments

Genetic Heterogeneity of MET-aberrant Non-Small Cell Lung Cancer and its Impact on the Outcome of Immunotherapy

*December 2020* Robust data on the outcome of MET-aberrant non-small cell lung cancer (NSCLC) with non-targeted therapies is limited, especially in consideration of the heterogeneity of MET-amplified tumors. METex14, METamp GCN≥10, and METamp GCN<10 represent subgroups of MET-dysregulated NSCLC with distinct molecular and clinical features. METex14 patients do not seem to benefit from immunotherapy in contrast…
laurabbook@gmail.com
January 21, 2021
Targeted Oncology
Increased Attention on Testing for Oncogenic Drivers in NSCLC Advances the Promise of Precision Medicine ResearchTreatments

Increased Attention on Testing for Oncogenic Drivers in NSCLC Advances the Promise of Precision Medicine

*December 2020* Identification of key oncogenic drivers and the development of targeted therapies with clinical activity in patients harboring actionable mutations have revolutionized the treatment paradigm in non–small cell lung cancer (NSCLC), redirecting attention toward advances in biomarker testing methodologies. This new focus is poised to foster granular refinement of…
laurabbook@gmail.com
January 21, 2021